Novartis Net Income From Continuing Ops vs Cost Of Revenue Analysis

NVS Stock  USD 100.13  1.55  1.52%   
Novartis financial indicator trend analysis is infinitely more than just investigating Novartis AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novartis AG ADR is a good investment. Please check the relationship between Novartis Net Income From Continuing Ops and its Cost Of Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novartis AG ADR Net Income From Continuing Ops account and Cost Of Revenue. At this time, the significance of the direction appears to have no relationship.
The correlation between Novartis' Net Income From Continuing Ops and Cost Of Revenue is 0.03. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Novartis AG ADR, assuming nothing else is changed. The correlation between historical values of Novartis' Net Income From Continuing Ops and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Novartis AG ADR are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income From Continuing Ops i.e., Novartis' Net Income From Continuing Ops and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.03
Relationship DirectionPositive 
Relationship StrengthInsignificant

Net Income From Continuing Ops

Cost Of Revenue

Cost of Revenue is found on Novartis AG ADR income statement and represents the costs associated with goods and services Novartis provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most indicators from Novartis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
At this time, Novartis' Selling General Administrative is comparatively stable compared to the past year. Discontinued Operations is likely to gain to about 5.5 B in 2024, whereas Enterprise Value is likely to drop slightly above 116 B in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit37.0B36.3B34.2B32.3B
Total Revenue52.9B51.8B46.7B46.2B

Novartis fundamental ratios Correlations

0.710.80.780.920.780.520.710.920.920.290.97-0.280.120.76-0.07-0.26-0.010.890.77-0.06-0.520.880.430.41-0.07
0.710.820.880.390.180.170.90.440.630.580.630.290.420.44-0.4-0.470.180.910.64-0.030.050.940.220.5-0.4
0.80.820.960.560.420.20.680.580.860.580.66-0.10.460.47-0.28-0.420.230.810.710.25-0.110.910.320.7-0.3
0.780.880.960.50.360.110.750.520.830.580.66-0.030.460.46-0.36-0.470.210.840.740.26-0.010.940.340.66-0.37
0.920.390.560.50.90.650.430.990.830.070.92-0.46-0.050.760.12-0.08-0.080.660.65-0.15-0.720.620.420.260.12
0.780.180.420.360.90.460.280.850.76-0.120.84-0.63-0.340.740.290.09-0.320.530.59-0.08-0.810.480.450.020.3
0.520.170.20.110.650.460.120.690.350.170.55-0.36-0.120.220.10.01-0.260.330.12-0.29-0.590.260.230.040.1
0.710.90.680.750.430.280.120.470.610.170.70.220.160.55-0.25-0.370.140.90.68-0.06-0.020.880.110.23-0.25
0.920.440.580.520.990.850.690.470.820.120.92-0.410.00.740.08-0.12-0.060.690.64-0.18-0.70.650.420.280.08
0.920.630.860.830.830.760.350.610.820.290.88-0.410.110.68-0.12-0.31-0.010.790.760.16-0.450.840.590.43-0.12
0.290.580.580.580.07-0.120.170.170.120.290.110.250.65-0.03-0.45-0.370.130.380.170.040.150.480.280.71-0.44
0.970.630.660.660.920.840.550.70.920.880.11-0.33-0.130.790.02-0.17-0.20.870.71-0.15-0.640.820.460.160.03
-0.280.29-0.1-0.03-0.46-0.63-0.360.22-0.41-0.410.25-0.330.39-0.04-0.49-0.410.260.01-0.19-0.450.580.0-0.290.12-0.5
0.120.420.460.46-0.05-0.34-0.120.160.00.110.65-0.130.39-0.15-0.44-0.40.810.160.250.280.530.29-0.190.91-0.48
0.760.440.470.460.760.740.220.550.740.68-0.030.79-0.04-0.150.0-0.24-0.160.660.58-0.47-0.540.60.450.110.0
-0.07-0.4-0.28-0.360.120.290.1-0.250.08-0.12-0.450.02-0.49-0.440.00.96-0.06-0.2-0.09-0.06-0.57-0.28-0.25-0.351.0
-0.26-0.47-0.42-0.47-0.080.090.01-0.37-0.12-0.31-0.37-0.17-0.41-0.4-0.240.96-0.07-0.33-0.220.01-0.43-0.4-0.31-0.380.96
-0.010.180.230.21-0.08-0.32-0.260.14-0.06-0.010.13-0.20.260.81-0.16-0.06-0.07-0.020.250.330.490.08-0.420.67-0.12
0.890.910.810.840.660.530.330.90.690.790.380.870.010.160.66-0.2-0.33-0.020.7-0.1-0.290.970.320.35-0.19
0.770.640.710.740.650.590.120.680.640.760.170.71-0.190.250.58-0.09-0.220.250.70.23-0.190.750.270.47-0.11
-0.06-0.030.250.26-0.15-0.08-0.29-0.06-0.180.160.04-0.15-0.450.28-0.47-0.060.010.33-0.10.230.310.04-0.130.29-0.08
-0.520.05-0.11-0.01-0.72-0.81-0.59-0.02-0.7-0.450.15-0.640.580.53-0.54-0.57-0.430.49-0.29-0.190.31-0.18-0.330.25-0.59
0.880.940.910.940.620.480.260.880.650.840.480.820.00.290.6-0.28-0.40.080.970.750.04-0.180.340.49-0.27
0.430.220.320.340.420.450.230.110.420.590.280.46-0.29-0.190.45-0.25-0.31-0.420.320.27-0.13-0.330.340.02-0.21
0.410.50.70.660.260.020.040.230.280.430.710.160.120.910.11-0.35-0.380.670.350.470.290.250.490.02-0.38
-0.07-0.4-0.3-0.370.120.30.1-0.250.08-0.12-0.440.03-0.5-0.480.01.00.96-0.12-0.19-0.11-0.08-0.59-0.27-0.21-0.38
Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets118.4B132.1B131.8B117.5B99.9B103.1B
Short Long Term Debt Total29.3B38.0B31.1B28.0B26.3B18.6B
Other Current Liab15.4B15.1B15.5B14.7B12.6B11.0B
Total Current Liabilities28.3B33.1B30.2B28.7B26.4B22.0B
Total Stockholder Equity55.5B56.6B67.7B59.3B46.7B57.2B
Property Plant And Equipment Net13.7B13.9B13.1B12.2B10.9B13.5B
Current Deferred Revenue236M114M56M123M98M135.9M
Net Debt18.2B28.4B18.7B20.4B13.0B11.0B
Retained Earnings59.3B57.2B71.0B63.5B49.6B58.0B
Accounts Payable5.4B5.4B5.6B5.1B4.9B4.2B
Cash11.1B9.7B12.4B7.5B13.4B7.7B
Non Current Assets Total88.9B102.4B86.1B80.5B69.5B73.2B
Non Currrent Assets Other738M892M2.2B1.1B2.2B2.1B
Cash And Short Term Investments11.4B11.6B28.3B18.9B14.0B13.1B
Net Receivables8.6B9.1B8.8B8.9B8.1B8.8B
Common Stock Total Equity969M944M936M913M821.7M776.8M
Common Stock Shares Outstanding2.3B2.3B2.3B2.2B2.1B1.9B
Short Term Investments334M1.9B15.9B11.4B569M540.6M
Liabilities And Stockholders Equity118.4B132.1B131.8B117.5B99.9B103.1B
Non Current Liabilities Total34.6B42.3B33.8B29.4B26.8B23.6B
Inventory6.0B7.1B6.7B7.2B5.9B6.0B
Other Current Assets2.7B2.9B2.8B2.9B2.0B2.3B
Other Stockholder Equity(59.4B)(53M)(48M)(92M)(41M)(43.1M)
Total Liab62.8B75.4B64.0B58.0B53.2B45.6B
Property Plant And Equipment Gross13.7B13.9B13.1B12.2B22.8B14.0B
Total Current Assets29.5B29.7B45.7B36.9B30.5B29.9B
Capital Stock936M913M901M890M825M767.6M
Short Term Debt7.3B10.1B6.6B6.2B6.3B6.3B
Common Stock936M913M901M890M825M767.6M
Accumulated Other Comprehensive Income54.6B55.7B66.8B58.5B(3.8B)(3.6B)
Intangible Assets28.8B36.8B34.2B31.6B26.9B22.4B
Other Liab12.5B14.4B9.2B7.6B8.7B8.5B
Other Assets14.8B14.7B12.4B4.8B5.6B10.1B
Long Term Debt20.4B26.3B22.9B20.2B18.4B12.8B
Good Will26.5B30.0B29.6B29.3B23.3B22.0B
Treasury Stock(69M)(80M)(53M)(48M)(41M)(43.1M)
Property Plant Equipment13.7B13.9B13.1B12.2B14.0B14.0B
Net Tangible Assets5.6B(5.5B)9.4B2.8B2.5B2.4B
Noncontrolling Interest In Consolidated Entity77M68M167M81M83M93.5M
Deferred Long Term Liab5.4B4.7B5.5B4.4B5.1B5.8B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.